SEC62 and breast cancer: For non-small cell lung cancer, head and neck squamous cell carcinomas, and breast cancer, high SEC62 expression levels are a strong predictor of poor clinical outcome and correlate significantly with the presence of lymph node and/or distant metastases [17,19,20,21,22].